Bronchiectasis & Nontuberculous Mycobacteria Research
Researchers in NYU Langone’s Division of Pulmonary, Critical Care, and Sleep Medicine conduct multidisciplinary translational and clinical research on bronchiectasis and nontuberculous mycobacteria (NTM).
The NYU Langone NTM and Bronchiectasis Multidisciplinary Program enables our scientists to integrate advances in research with clinical care applied to a large cohort of subjects with NTM disease with or without bronchiectasis. This cohort provides the platform needed to institute both translational research and clinical trials. Doreen J. Addrizzo-Harris, MD, principal investigator, and her colleague David L. Kamelhar, MD, conduct prospective evaluation of patients with NTM infection, collecting extensive clinical data and data from questionnaires that facilitate study of the natural history of NTM disease. Other members of the research team include Leopoldo N. Segal, MD; Ashwin Basavaraj, MD; Stephanie Lau, MD, and Amy Levinger, NP.
Dr. Kamelhar has contributed to the growth of this multidisciplinary program, which is staffed by swallowing, esophageal–gastric, and imaging specialists. He is interested in understanding the role of swallowing dysfunction, in addition to laryngopharyngeal and gastroesophageal reflux, and in the evolution and progression of NTM disease.
As part of this program, Dr. Segal and his colleagues at the Segal Lab perform research on the airway microbiome. Dr. Segal is evaluating how a disrupted lung microbiome may be necessary for the development of clinically evident NTM infection. In addition, he is in charge of developing a biorepository of airway samples collected during the initiation and maintenance of antimycobacterial treatment. The goal is to identify microbial signatures associated with successful suppressive treatment or disease progression that may facilitate identification of new targets for treatment in individual patients.
Dr. Addrizzo-Harris also participates in multicenter studies evaluating novel antibiotic approaches in refractory NTM disease. She serves as primary investigator for the NYU Langone section of the COPD Foundation’s Bronchiectasis and NTM Research Registry. NYU Langone is one of the largest contributors to the registry.
Adelman MH and Addrizzo-Harris DJ. Management of nontuberculous mycobacterial pulmonary disease. Curr Opin Pulm Med. 2018. DOI.
Griffith DE … Winthrop KL. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018. DOI.
Sulaiman I … Segal LN. Evaluation of the airway microbiome in nontuberculous mycobacteria. Eur Respir J. 2018. DOI.
Basavaraj A … Kamelhar D. Effects of chest physical therapy in patients with non-tuberculous mycobacteria. Int J Resp Pulm Med. 2017. DOI.
Olivier KN … Wallace RJ. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017. DOI.
Wu BG and Segal LN. Lung microbiota and its impact on the mucosal immune phenotype. Microbiol Spectr. 2017. DOI.